Express Mail Label No.: EV058116135US Date of Deposit: February 19, 2002 Attorney Docket No. 23135-502 (NOV-2)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

PPLICANTS:

Conrad et al.

SERIAL NUMBER:

09/490,700

EXAMINER:

Natalie A. Davis

FILING DATE:

January 24, 2000

ART UNIT:

1642

For:

METHODS FOR DIAGNOSIS AND THERAPY OF AUTOIMMUNE

DISEASE, SUCH AS INSULIN DEPENDENT DIABETES MELLITUS,

INVOLVING RETROVIRAL SUPERANTIGENS

Commissioner for Patents Washington, D.C. 20231

RECEIVED

MAR 0 4 2002

TECH CENTER 1600/2900

STATEMENT IN SUPPORT OF COMPUTER READABLE FORM SUBMISSION UNDER 37 C.F.R. § 1.821(f)

I hereby state that the content of the paper and computer readable forms of the Sequence Listing, submitted in the above-identified application in accordance with 37 C.F.R. § 1.821(c) and 1.821(e), respectively, are the same. No new matter is added.

Respectfully submitted,

Date: February 19, 2002

Kristin E. Konzak, Reg. No. 44,848

Attorney/Agent for Applicant

c/o Mintz, Levin

One Financial Center Boston, MA 02111

Telephone (617) 542 6000

Fax

(617) 542 2241

	Express Mail Labol: EV 058111		SITED: 2/19/02
		Application No.	Applicant(s)
4	ેંદ _∖ Notice to Comply	09/490 700	A 4 11 15
ĵ	الله الله الله الله الله الله الله الله	Notalie Doni	Art Unit
			ADDI ICATIONS
NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE			
	DISCLOSURES		
	Applicant must file the items indicated below within the time period set the Office action to which the Notice is attached to avoid abandonment under 35 U.S.C. § 133 (extensions of time may be obtained under the provisions of 37 CFR 1.136(a)).		
	The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):		
	1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998).		
	2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).		
	3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).		
	4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."		
	5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).		
	6. The paper copy of the "Sequence Listing" is not the same as the computer readable from of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).		
	7. Other:		
	Applicant Must Provide: Applicant Must Provide: An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".		
	An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.		
	A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).		
For questions regarding compliance to these requirements, please contact:			ase contact:
For Rules Interpretation, call (703) 308-4216			
	For CRF Submission Help, call (703	•	RECEIVED
	Patentin Software Program Support Technical Assistance		00 MAR 0 4 2002
	To Purchase Patentin Software		

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR REPLY ECH CENTER 1600/2900